Researchers at KAIST have developed a breakthrough therapy that reprograms immune cells already inside tumors into powerful cancer fighters using a single injection. The approach eliminates the need for expensive and time-consuming lab-based cell extraction.
The team led by Professor Ji-Ho Park created lipid nanoparticles that deliver mRNA encoding CAR (chimeric antigen receptor) proteins along with an immune-boosting STING agonist directly to tumor-associated macrophages. These macrophages, normally suppressed by the tumor environment, absorb the nanoparticles and transform into "enhanced CAR-macrophages" capable of recognizing and destroying cancer cells.
In melanoma animal models, tumor growth was significantly suppressed. Remarkably, the immune response extended beyond the treated tumor site, suggesting potential for targeting metastatic cancers as well.
The research was published in ACS Nano with Jun-Hee Han as first author.
